Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

NCT00698685 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Pentostatin/alemtuzumab regimen had greater risk of graft failure.

Conditions

Leukemia
Lymphoma
Hodgkin's Disease
Hematologic Neoplasms
Multiple Myeloma
Carcinoma, Renal Cell

Interventions

DRUG: Pentostatin
BIOLOGICAL: Alemtuzumab
PROCEDURE: Allogeneic hematopoietic stem cell transplantation

Sponsor

University of Arizona

Collaborators

[object Object]